The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

The repertoire of monoclonal antibodies and other biologic therapies targeted at precise
components of the immune response continues to expand rapidly. In theory, these therapies …

Biologics are increasingly becoming part of routine disease management. As more agents
are developed, the challenge of keeping track of indications and side effects is growing …

The development of biologic therapies targeting proinflammatory mediators has led to
significant advances in the treatment of immune-mediated inflammatory diseases (IMIDs) …

The advances in cancer biology and pathogenesis during the past two decades, have
resulted in immunotherapeutic strategies that have revolutionized the treatment of …

The last decade has seen the emergence of immunomodulators as promising therapeutic
agents in infectious diseases. A diverse array of recombinant, synthetic and natural …

Microorganisms responsible for the infectious complications associated with anticytokine
therapy are generally intracellular pathogens or pathogens that commonly exist in a chronic …

The emergence of multiantibiotic-resistant bacteria, often referred to as superbugs, is
leading to infections that are increasingly difficult to treat. Further, bacteria have evolved …

Context Biologicals are a relatively new class of medicines that carry specific risks (eg,
immunogenicity). However, limited information is available on the nature and timing of safety …

The introduction of novel agents to the therapeutic armamentarium for oncologic,
rheumatologic, and neurologic disorders has resulted in major clinical advances. These …